Compare
Axsome Therapeutics, Inc. vs TG Therapeutics, Inc. vs Opko Health, Inc. vs Insmed Inc
| Latest fiscal year | Axsome Therapeutics, Inc. AXSM | TG Therapeutics, Inc. TGTX | Opko Health, Inc. OPK | Insmed Inc INSM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $638.50M | $616.29M | $606.88M | $606.42M |
| Revenue growth (YoY) | +65.5% | +87.3% | -14.9% | +66.7% |
| Gross margin | n/a | 83.7% (computed) | 33.9% | 79.7% (computed) |
| Operating margin | -26.1% | 20.0% | -19.3% | -205.6% |
| Net margin | -28.7% | 72.6% | -37.2% | -210.5% |
| Net income | -$183.17M | $447.18M | -$225.68M | -$1.28B |
| EPS (Diluted) | -$3.68 | $2.77 | -$0.30 | -$6.42 |
| Operating cash flow | -$93.41M | -$24.77M | -$178.54M | -$935.01M |
| Free cash flow | -$93.89M | -$24.99M | -$190.82M | -$967.58M |
| Cash & equivalents | $322.93M | $79.15M | $364.41M | $510.44M |
| Total assets | $689.80M | $1.06B | $1.93B | $2.26B |
| Total liabilities | $601.51M | $415.23M | $663.99M | $1.53B |
| Shareholders' equity | $88.30M | $648.02M | $1.27B | $738.98M |
| Return on year-end equity | -207.5% | 69.0% | -17.8% | -172.8% |
| Shares outstanding | 50.88M | 155.31M | n/a | 214.26M |
Revenue, most recent five fiscal years
| Fiscal year | Axsome Therapeutics, Inc. | TG Therapeutics, Inc. | Opko Health, Inc. | Insmed Inc |
|---|---|---|---|---|
| Latest | $638.50M Ended 2025-12-31 | $616.29M Ended 2025-12-31 | $606.88M Ended 2025-12-31 | $606.42M Ended 2025-12-31 |
| 1 year earlier | $385.69M Ended 2024-12-31 | $329.00M Ended 2024-12-31 | $713.14M Ended 2024-12-31 | $363.71M Ended 2024-12-31 |
| 2 years earlier | $270.60M Ended 2023-12-31 | $233.66M Ended 2023-12-31 | $863.50M Ended 2023-12-31 | $305.21M Ended 2023-12-31 |
| 3 years earlier | $50.04M Ended 2022-12-31 | $2.79M Ended 2022-12-31 | $1.00B Ended 2022-12-31 | $245.36M Ended 2022-12-31 |
| 4 years earlier | n/a | $6.69M Ended 2021-12-31 | $1.77B Ended 2021-12-31 | $188.46M Ended 2021-12-31 |